The effect of pre-existing immunity on the capacity of influenza virosomes to induce cytotoxic T lymphocyte activity

Vaccine

Volumn 26, Issue 19, 2008, Pages 2314-2321

  de Mare, Arjan ^a   Bungener, Laura B ^a   Regts, Joke ^a   de Vries Idema, Jacqueline ^a   van der Zee, Ate G J ^a   Wilschut, Jan ^a   Daemen, Toos ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

CTL; Pre existing immunity; Virosome

Indexed keywords

INFLUENZA VIROSOME; OVALBUMIN; VIROSOME;

ANALYTIC METHOD; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG DELIVERY SYSTEM; FEMALE; HUMORAL IMMUNITY; IMMUNITY; IMMUNIZATION; INFLUENZA VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANIMALS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; IMMUNIZATION, SECONDARY; INFLUENZA VACCINES; INTERFERON TYPE II; MICE; MICE, INBRED C57BL; ORTHOMYXOVIRIDAE INFECTIONS; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; VIROSOMES;

EID: 42649105437     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.03.002     Document Type: Article

References (49)

1. Bron R., Ortiz A., Dijkstra J., Stegmann T., and Wilschut J. Preparation, properties, and applications of reconstituted influenza virus envelopes (virosomes). Methods Enzymol 220 (1993) 313-331
2. Shimizu K., Hosaka Y., and Shimizu Y.K. Solubilization of envelopes of HVJ (Sendai virus) with alkali-emasol treatment and reassembly of envelope particles with removal of the detergent. J Virol 9 5 (1972) 842-850
3. Eidelman O., Schlegel R., Tralka T.S., and Blumenthal R. pH-dependent fusion induced by vesicular stomatitis virus glycoprotein reconstituted into phospholipid vesicles. J Biol Chem 259 7 (1984) 4622-4628
4. Haddad R.S., and Hutt-Fletcher L.M. Depletion of glycoprotein gp85 from virosomes made with Epstein-Barr virus proteins abolishes their ability to fuse with virus receptor-bearing cells. J Virol 63 12 (1989) 4998-5005
5. Cornet B., Vandenbranden M., Cogniaux J., Giurgea L., Dekegel D., and Ruysschaert J.M. Virosomes reconstituted from human immunodeficiency virus proteins and lipids. Biochem Biophys Res Commun 167 1 (1990) 222-231
6. Munoz-Barroso I., Cobaleda C., Zhadan G., Shnyrov V., and Villar E. Dynamic properties of Newcastle disease virus envelope and their relations with viral hemagglutinin-neuraminidase membrane glycoprotein. Biochim Biophys Acta 1327 1 (1997) 17-31
7. Almeida J.D., Edwards D.C., Brand C.M., and Heath T.D. Formation of virosomes from influenza subunits and liposomes. Lancet 2 7941 (1975) 899-901
8. Stegmann T., Morselt H.W., Booy F.P., van Breemen J.F., Scherphof G., and Wilschut J. Functional reconstitution of influenza virus envelopes. EMBO J 6 9 (1987) 2651-2659
9. Bron R., Ortiz A., and Wilschut J. Cellular cytoplasmic delivery of a polypeptide toxin by reconstituted influenza virus envelopes (virosomes). Biochemistry 33 31 (1994) 9110-9117
10. Skehel J.J., and Wiley D.C. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 69 (2000) 531-569
11. Bungener L., Huckriede A., Wilschut J., and Daemen T. Delivery of protein antigens to the immune system by fusion-active virosomes: a comparison with liposomes and ISCOMs. Biosci Rep 22 2 (2002) 323-338
12. Huckriede A., Bungener L., Daemen T., and Wilschut J. Influenza virosomes in vaccine development. Methods Enzymol 373 (2003) 74-91
13. Felnerova D., Viret J.F., Gluck R., and Moser C. Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr Opin Biotechnol 15 6 (2004) 518-529
14. Daemen T., de Mare A., Bungener L., de Jonge J., Huckriede A., and Wilschut J. Virosomes for antigen and DNA delivery. Adv Drug Deliv Rev 57 3 (2005) 451-463
15. de Jonge J., Holtrop M., Wilschut J., and Huckriede A. Reconstituted influenza virus envelopes as an efficient carrier system for cellular delivery of small-interfering RNAs. Gene Ther 13 5 (2006) 400-411
16. Bungener L., Serre K., Bijl L., Leserman L., Wilschut J., Daemen T., et al. Virosome-mediated delivery of protein antigens to dendritic cells. Vaccine 20 17-18 (2002) 2287-2295
17. Schwaninger R., Waelti E., Zajac P., Wetterwald A., Mueller D., and Gimmi C.D. Virosomes as new carrier system for cancer vaccines. Cancer Immunol Immunother 53 11 (2004) 1005-1017
18. Bungener L., Huckriede A., de Mare A., Vries-Idema J., Wilschut J., and Daemen T. Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity. Vaccine 23 10 (2005) 1232-1241
19. Bungener L., de Mare A., de Vries-Idema J., Sehr P., van der Zee A., Wilschut J., et al. A virosomal immunization strategy against cervical cancer and pre-malignant cervical disease. Antivir Ther 11 6 (2006) 717-727
20. Tamura M., Webster R.G., and Ennis F.A. Subtype cross-reactive, infection-enhancing antibody responses to influenza A viruses. J Virol 68 6 (1994) 3499-3504
21. Takada A., and Kawaoka Y. Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Rev Med Virol 13 6 (2003) 387-398
22. Ochiai H., Kurokawa M., Kuroki Y., and Niwayama S. Infection enhancement of influenza A H1 subtype viruses in macrophage-like P388D1 cells by cross-reactive antibodies. J Med Virol 30 4 (1990) 258-265
23. Tamura M., Webster R.G., and Ennis F.A. Antibodies to HA and NA augment uptake of influenza A viruses into cells via Fc receptor entry. Virology 182 1 (1991) 211-219
24. Bessis N., GarciaCozar F.J., and Boissier M.C. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther 11 Suppl. 1 (2004) S10-S17
25. Tsai V., Johnson D.E., Rahman A., Wen S.F., LaFace D., Philopena J., et al. Impact of human neutralizing antibodies on antitumor efficacy of an oncolytic adenovirus in a murine model. Clin Cancer Res 10 21 (2004) 7199-7206
26. Sumida S.M., Truitt D.M., Kishko M.G., Arthur J.C., Jackson S.S., Gorgone D.A., et al. Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J Virol 78 6 (2004) 2666-2673
27. Lauterbach H., Ried C., Epstein A.L., Marconi P., and Brocker T. Reduced immune responses after vaccination with a recombinant herpes simplex virus type 1 vector in the presence of antiviral immunity. J Gen Virol 86 Pt 9 (2005) 2401-2410
28. Harrington L.E., Most Rv R., Whitton J.L., and Ahmed R. Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope. J Virol 76 7 (2002) 3329-3337
29. Lowenstein P.R. Input virion proteins: cryptic targets of antivector immune responses in preimmunized subjects. Mol Ther 9 6 (2004) 771-774
30. Manno C.S., Pierce G.F., Arruda V.R., Glader B., Ragni M., Rasko J.J., et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 12 3 (2006) 342-347
31. Chen J., Wu Q., Yang P., Hsu H.C., and Mountz J.D. Determination of specific CD4 and CD8 T cell epitopes after. Mol Ther 13 2 (2006) 260-269
32. Leserman L.D., Weinstein J.N., Blumenthal R., and Terry W.D. Receptor-mediated endocytosis of antibody-opsonized liposomes by tumor cells. Proc Natl Acad Sci USA 77 7 (1980) 4089-4093
33. Aragnol D., and Leserman L.D. Immune clearance of liposomes inhibited by an anti-Fc receptor antibody in vivo. Proc Natl Acad Sci USA 83 8 (1986) 2699-2703
34. Yan X., Scherphof G.L., and Kamps J.A. Liposome opsonization. J Liposome Res 15 1-2 (2005) 109-139
35. Da Silva D.M., Schiller J.T., and Kast W.M. Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines. Vaccine 21 23 (2003) 3219-3227
36. Liu X.S., Xu Y., Hardy L., Khammanivong V., Zhao W., Fernando G.J., et al. IL-10 mediates suppression of the CD8 T cell IFN-gamma response to a novel viral epitope in a primed host. J Immunol 171 9 (2003) 4765-4772
37. Ruedl C., Schwarz K., Jegerlehner A., Storni T., Manolova V., and Bachmann M.F. Virus-like particles as carriers for T-cell epitopes: limited inhibition of T-cell priming by carrier-specific antibodies. J Virol 79 2 (2005) 717-724
38. Moore M.W., Carbone F.R., and Bevan M.J. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 54 6 (1988) 777-785
39. Böttcher C.J.F., van Gent C.M., and Fries C. A rapid and sensitive sub-micro phosphorous determination. Anal Chim Acta (1961) 24203-24204
40. Peterson G.L. A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem 83 2 (1977) 346-356
41. Haan L., Verweij W.R., Holtrop M., Brands R., van Scharrenburg G.J., Palache A.M., et al. Nasal or intramuscular immunization of mice with influenza subunit antigen and the B subunit of Escherichia coli heat-labile toxin induces IgA- or IgG-mediated protective mucosal immunity. Vaccine 19 20-22 (2001) 2898-2907
42. Miyahira Y., Murata K., Rodriguez D., Rodriguez J.R., Esteban M., Rodrigues M.M., et al. Quantification of antigen specific CD8+ T cells using an ELISPOT assay. J Immunol Methods 181 1 (1995) 45-54
43. Hobson D., Curry R.L., Beare A.S., and Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 70 4 (1972) 767-777
44. Turner S.J., Kedzierska K., La Gruta N.L., Webby R., and Doherty P.C. Characterization of CD8+ T cell repertoire diversity and persistence in the influenza A virus model of localized, transient infection. Semin Immunol 16 3 (2004) 179-184
45. Doherty P.C., Turner S.J., Webby R.G., and Thomas P.G. Influenza and the challenge for immunology. Nat Immunol 7 5 (2006) 449-455
46. Stegmann T., Schoen P., Bron R., Wey J., Bartoldus I., Ortiz A., et al. Evaluation of viral membrane fusion assays Comparison of the octadecylrhodamine dequenching assay with the pyrene excimer assay. Biochemistry 32 42 (1993) 11330-11337
47. Brady L.J. Antibody-mediated immunomodulation: a strategy to improve host responses against microbial antigens. Infect Immun 73 2 (2005) 671-678
48. Perrin-Cocon L.A., Villiers C.L., Salamero J., Gabert F., and Marche P.N. B cell receptors and complement receptors target the antigen to distinct intracellular compartments. J Immunol 172 6 (2004) 3564-3572
49. Simitsek P.D., Campbell D.G., Lanzavecchia A., Fairweather N., and Watts C. Modulation of antigen processing by bound antibodies can boost or suppress class II major histocompatibility complex presentation of different T cell determinants. J Exp Med 181 6 (1995) 1957-1963